Published online Jan 26, 2024. doi: 10.12998/wjcc.v12.i3.565
Peer-review started: September 8, 2023
First decision: November 9, 2023
Revised: November 22, 2023
Accepted: January 3, 2024
Article in press: January 3, 2024
Published online: January 26, 2024
Processing time: 131 Days and 21.5 Hours
Marginal zone lymphoma (MZL) is an indolent subtype of non-Hodgkin lym
This study reports a case of MZL with generalized skin rashes accompanied by pruritus and purulent discharge. First-line treatment with rituximab combined with zanubrutinib had poor effects. However, after switching to obinutuzumab combined with zanubrutinib, the case was alleviated, and the rashes disappeared.
For patients with advanced stage MZL not benefiting from type I anti-CD20 monoclonal antibody (mAb) combination therapy, switching to a type II anti-CD20 mAb combination regimen may be considered. This approach may provide a new perspective in the treatment of MZL.
Core Tip: This paper reports a case of Marginal zone lymphoma (MZL) with generalized skin rashes accompanied by pruritus and purulent discharge. First-line treatment with rituximab combined with zanubrutinib had poor effects. However, after switching to obinutuzumab combined with zanubrutinib, the case was alleviated, and the rashes disappeared. Therefore, in patients with advanced stage MZL not benefiting from type I anti-CD20 monoclonal antibody (mAb) combination therapy, switching to a type II anti-CD20 mAb combination regimen may be considered. This approach may provide a new perspective in the treatment of MZL.